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Dendritic cell activation of CD4T cells in the lymph node draining a site of infection or
vaccination is widely considered the central event in initiating adaptive immunity. The
accepted dogma is that this occurs by stimulating local activation and antigen acquisition
by dendritic cells, with subsequent lymph node migration, however the generalizability of
this mechanism is unclear. Here we show that in some circumstances antigen can bypass
the injection site inflammatory response, draining freely and rapidly to the lymph nodes
where it interacts with subcapsular sinus (SCS) macrophages resulting in their death.
Debris from these dying SCS macrophages is internalized by monocytes recruited from
the circulation. This coordinated response leads to antigen presentation by monocytes
and interactions with naïve CD4T cells that can drive the initiation of T cell and B cell
responses. These studies demonstrate an entirely novel pathway leading to initiation of
adaptive immune responses in vivo.
Keywords: antigen processing and presentation, T cell activation, monocytes, subcapsular sinus macrophages,
adjuvants, immunologic
INTRODUCTION
Here we present a novel cellular pathway of antigen presentation and CD4T cell activation
which challenges the current dogma. T cell responses to peripheral antigen challenge, either
against an invading pathogen or vaccination, are initiated in the draining lymph node. A
canonical model has been proposed, whereby dendritic cells (DCs) acquire antigen in the
tissue and subsequently migrate to the lymph node to interact with and activate T cells (1–3).
These processes appear to be influenced by the local inflammatory response in the tissue
infection/injection site in response to pathogen and/or damage associated molecular patterns
(PAMPS or DAMPS, respectively) (4–6). The combined ability of DCs to sense and respond
to challenges in tissues and activate naïve T cells in the lymph node means they have been
proposed to have a central role as a key “bridge” between the innate and adaptive immune
responses as well as the tissue and the lymphoid system (7–11). However, whether migratory
DCs play a role in the initiation of CD4 mediated adaptive immune responses in response to
all stimuli remains unclear. For example, their role the mechanism of action of the clinically
approved adjuvants such Alum is questioned by the observation that the adaptive immune
response is not affected by removal of the injection site 2 h after injection, before significant
cell migration can occur (12). Furthermore, small particles typically those less than 100 nm
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such as Virus Like Particles (e.g., Hepatitis or Papilloma virus
vaccines) or soluble antigens may drain freely to the lymph
nodes via the lymphatic vessels independently of migratory cells
(13–15). These studies suggest that in some cases, CD4T cell
responses may be initiated partially or completely independently
of migratory DC populations.
To test this further we employed ISCOMATRIXTM adjuvant
(ISCOMATRIX), a novel nanoparticulate adjuvant (40–50 nm
diameter) composed of cholesterol, phospholipids and saponin
with both immunostimulatory and antigen delivery activity.
Immunization with ISCOMATRIX has been shown to induce
mixed Th1 and Th2 antibody responses and CD8T cell
responses (16). MHCII has also been shown to be essential
for ISCOMATRIX driven CD8T cells responses (17) therefore
CD4T cells must also be critical for ISCOMATRIX function.
However, the mechanism whereby ISCOMATRIX affects antigen
presentation on MHCII and activates CD4T cell responses
has not been established. Here, we reveal an alternative
pathway for the induction of adaptive immune responses
by demonstrating that ISCOMATRIX induced inflammation
at the site of inoculation is not required for the induction
of the adaptive immune response but rather ISCOMATRIX
induces inflammation and cell death directly within the
draining lymph node. We subsequently show that, rather
than migratory DCs, the important cell type presenting
antigen on MHCII to CD4T cells are monocytes that
have been recruited directly to the lymph node following
immunization.
RESULTS
Co-administered Soluble Antigen and
Adjuvant Are Not Retained at the Injection
Site, Draining Rapidly to the Lymph Node
It has been suggested that the prolonged presence of antigen
is important in driving an adaptive immune response, with
the formation of an antigen depot at the injection site often
considered to be a key element in the mode of action of adjuvants
(18, 19). We therefore utilized whole body imaging of mice
following the injection of fluorescently labeled antigen (OVA-
790) and/ or ISCOMATRIX (ISCOMATRIX-647) into the ear
pinnae of C57BL/6 mice to track the location of a soluble antigen
and adjuvant. Image analysis demonstrated that the presence of
antigen in the ear is not prolonged by ISCOMATRIX with the
fluorescence intensity of both antigen and adjuvant returning
to near background levels within 24 h (Figures 1A,B,E,F).
OVA-790 and ISCOMATRIX-647 were rapidly displaced to
the superficial cervical lymph node draining the ear within
15min of injection. The fluorescence signal from both OVA-790
and ISCOMATRIX-647 remained detectable within the lymph
node for 48 h, the presence of ISCOMATRIX however does
not alter the magnitude or duration of the OVA-790 signal
(Figures 1C,D,E,F). These data suggest that ISCOMATRIX does
not form an antigen depot at the injection site or in the draining
lymph node.
Neutrophils and Monocytes Are Recruited
to the Antigen/Adjuvant Injection Site and
Draining Lymph Node
Localized inflammation at the injection site may also enhance the
development of an adaptive immune response in the draining
lymph node following immunization (17, 20). Compared with
injection with OVA alone, ear pinnae injected with OVA-
ISCOMATRIX demonstrated a significant early neutrophil
influx, starting at 4 h and peaking at 24. This was followed by
an influx of CD11b+ cells, presumably monocytes at 24 and
48 h (Figure 2A). Analysis of the lymph node draining the ear
showed that ISCOMATRIX stimulated a similar but shorter-
lived infiltration of neutrophils at 4 h followed by an increase in
CD11b+ cells. Further analysis revealed the majority of CD11b+
infiltrating cells were CD64+Ly6Chi monocytes, their numbers
peaking at 24 h and beginning to decline by 48 h (Figure 2B).
Antigen/Adjuvant Injection Site
Inflammation Does Not Contribute to Cell
Migration or Activation of Immune
Responses in the Draining Lymph Node
Injection site inflammation is thought to drive skin resident
DC migration and recruitment of inflammatory cells that may
subsequently migrate to the lymph node (20). In order to
definitively identify cells migrating from the injection site to
the draining lymph node, we utilized the Kaede transgenic
mouse. These mice ubiquitously express the Kaede fluorescent
protein that normally emits in the green spectrum (518 nm),
however Kaede can undergo UV induced fission to a form
that fluoresces red (582 nm) (21). We immunized Kaede mice
in the left footpad, with PBS and ISCOMATRIX on the right.
Both feet were photoswitched using a UV laser either prior to
immunization or 8, 12, or 24 h post-immunization. The draining
lymph node was then analyzed for the presence of injection site
derived, Kaede red cells at 24 or 48 h post-immunization. Mice
immunized with Alum/LPS were used as a positive control. In
ISCOMATRIX treated tissue no increase in the number of red
cells was observed compared with the PBS treated control lymph
node at any time point tested suggesting that ISCOMATRIX does
not stimulate cell migration from the injection site to the lymph
node (Figure 3A). We could clearly identify an increase in the
percentage of Kaede red cells in the draining lymph node of
mice immunized with the positive control, Alum/LPS at both
time points assessed (Figure 3B). While these studies definitively
confirmed that ISCOMATRIX does not stimulate cell migration
from the injection site to the lymph node, the inflammatory
environment identified at the injection site could still contribute
to or influence the immune response developing within the
lymph node, for example via soluble mediators (22, 23). To
analyse this, we immunized mice with OVA/ISCOMATRIX and
then performed injection site removal. Ablation of the injection
site within 15min of the administration of OVA/ISCOMATRIX
failed to significantly alter antigen-specific IgG1 levels at 14 days
(Figure 3C) demonstrating that events at injection site are not
required for ISCOMATRIX adjuvant activity and are therefore
not a prerequisite to drive adaptive immune responses to antigen.
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FIGURE 1 | ISCOMATRIX does not alter the passage of soluble antigen from the injection site to the lymph node. Graphs show fluorescence intensity of (A)
ISCOMATRIX-647 detected at 630 ± 17.5 nm and (B) OVA-790 detected at 830 ± 17.5 nm in the ear pinnae and (C) ISCOMATRIX-647 and (D) OVA-790 in the
draining cervical lymph node over time. Representative X-ray images with pseudocoloured fluorescence images overlaid showing (E) ISCOMATRIX-647 fluorescence
(630 ± 17.5 nm) and (F) OVA-790 fluorescence (830 ± 17.5 nm) over time following injection in the ear pinnae with OVA-790 alone, ISCOMATRIX-647 alone or
OVA-790/ISCOMATRIX-647. Three animals were imaged at each time point. IMX = ISCOMATRIXTM adjuvant, *P < 0.05.
Antigen/Adjuvant Localizes to the
Subcapsular Sinus (SCS) and Causes Loss
of CD169+ Macrophages
The studies above demonstrate that neither tissue resident
cells nor the inflammatory reaction induced by adjuvant at
the injection site are required to develop an adaptive immune
response to co-administered antigen. Therefore, following the
rapid displacement of antigen and ISCOMATRIX to the draining
lymph node, the events occurring within the draining lymph
node appear sufficient to drive an adaptive response. To
localize ISCOMATRIX within the draining lymph node we
administered a PE labeled anti-CD169 antibody to mice via
the footpad to label subcapsular sinus (SCS) macrophages in
the draining popliteal lymph node. Approximately 1 h after
immunization with ISCOMATRIX-647-OVA, intravital imaging
revealed adjuvant localization to the sinus region of the
lymph node and colocalization with CD169+ SCS macrophages
(Figure 4A). Subsequently, analysis of lymph node tissue sections
prepared 24 h after ISCOMATRIX immunization demonstrated a
reduction in the SCSmacrophage population compared with PBS
treated controls (Figure 4B). Intravital imaging at approximately
2 h following administration of the cell impermeable DNA dye,
Sytox Orange, showed that cells labeled with ISCOMATRIX-
647 were also positive for the Sytox Orange suggesting that
these cells were dying (Figure 4C). Flow cytometry confirmed
an almost complete absence of CD11b+ CD169+ cells 24 h post
ISCOMATRIX immunization (Figures 4D,E). Kinetic analysis
demonstrated that loss of SCS macrophages (CD11b+ CD169+)
began as soon as 4 h post-immunization with ISCOMATRIX,
with an almost total absence by 12 h (Figure 4F). A significant
reduction in the percentage of these cells was maintained until
14 days post-immunization when they had recovered to levels
similar to that observed in the contralateral ear draining lymph
node (Figure 4G).
SCS Macrophages Killed by Adjuvant
Action Are Taken Up by Monocytes
Recruited to T Cell Dependent Areas
To identify where SCS macrophages and/or their debris traffic
to following immunization, we labeled them in vivo with a
fluorescently labeled anti-CD169 (eFluor660) antibody prior to
immunization. Twenty-four hours later, the draining lymph
nodes were harvested and stained ex vivo with antibodies
to CD11b, CD64, Ly6C, and CD169 (conjugated to PE)
followed by flow cytometric analysis. At 24 h post-immunization
with ISCOMATRIX, the CD169 in vivo label (Figure 5A)
was found in cells that were ex vivo CD169- but CD64+
and Ly6C hi (Figure 5B). By contrast, the CD169 in vivo
positive cells (Figure 5A) from PBS treated lymph node were
ex vivo CD169 positive, CD64-and Ly6C neg-low (Figure 5B).
Furthermore, CD11b-CD11c+ DCs at 4 h post-immunization
with ISCOMATRIX acquire the CD169 in vivo label at
levels similar to that observed in the PBS treated mice
(Supplementary Figure 1A), by 24 h the ISCOMATRIX treated
mice have lost the CD169 in vivo label from their CD11b-
CD11c+DCs (Supplementary Figure 1B). The degree of CD169
in vivo fluorescence labeling in these DCs is substantially
lower than that observed in the CD11b+CD64+ monocytes
(Supplementary Figure 1C).
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FIGURE 2 | Neutrophils and CD11b+ cells are recruited to both the injection site and to the draining lymph node. (A) Representative flow cytometry plots showing the
recruitment of neutrophils and CD11b+ cells in the injection site at 4, 24, and 48 h following immunization with OVA/PBS (top) or OVA/ISCOMATRIX (bottom).
Absolute numbers are shown in the graphs on the right. (B) Representative flow cytometry plots showing the recruitment of neutrophils and CD11b+ cells in the
draining cervical lymph node at 4, 24, and 48 h following immunization with OVA/PBS (top left) or OVA/ISCOMATRIX (bottom left). Further representative plots show
the identification of the majority of the CD11b cells in the OVA/ISCOMATRIX treated lymph node at 24 h were monocytes (CD64+Ly6C high) (top right). Absolute
numbers of Neutrophils and monocytes recruited to the draining lymph node in response to OVA/PBS and OVA/ISCOMATRIX are shown (bottom left). Data shown is
from 3 mice per group pooled and is representative of 5 independent experiments. IMX = ISCOMATRIXTM adjuvant.
ImageStream analysis of in vivo anti-CD169 eFluor660 labeled
lymph nodes at 24 h post-immunization with ISCOMATRIX
shows the e660 label was present in internal compartments of
CD64+CD11b+ cells (Figure 5C), while in mice treated with the
PBS control the e660 label was detected predominantly in CD64-
CD11b+ cells suggesting that the SCSmacrophages had taken up
the antibody label directly (Figure 5D).
This data suggests that following treatment with
ISCOMATRIX, CD169+ SCS macrophages die and are taken up
by monocytes. We hypothesized that dying SCS macrophages
could carry antigen and may furthermore be a source of DAMPS
within the lymph node providing an inflammatory signal to
facilitate T cell activation.
Adjuvant Can Promote, Monocyte
Acquisition, Processing and Presentation
of Antigen in the Context of MHCII
Classically, antigen presentation to T cells in the lymph node
was thought to be performed by DCs (1, 9, 24). However,
we previously observed (Figure 2) that OVA/ISCOMATRIX
stimulates significant recruitment of monocytes to the lymph
node, which were clearly not injection site derived (Figure 3).
To investigate the role of monocytes in the induction of T cell
responses triggered by ISCOMATRIX we used the E-alpha:
YAe model, where presentation of the peptide on MHCII
may be detected by flow cytometry using the YAe antibody
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FIGURE 3 | The injection site is not required for ISCOMATRIX adjuvant activity. (A) Representative flow cytometry plots showing Kaede red vs. Kaede green in the
popliteal lymph node (top panels) draining the PBS injected (left) and the ISCOMATRIX (right) injected footpad, below plots showing the percentage of the leukocytes
in the draining lymph nodes at 24 h following photoswitching immediately prior (middle left), 8 h post (middle right) 12 h post (bottom left) immunization or at 48 h from
mice photoswitched at 24 h (bottom right). (B) Representative flow cytometry plots showing Kaede red vs. Kaede green in the popliteal lymph node (top panels)
draining the PBS injected (left) and the ALUM/LPS (right) injected footpad, below plots showing the percentage of the leukocytes in the draining lymph nodes at 24 h
following photoswitching 8 h post (bottom left) and 12 h post (bottom right) immunization. (C) Serum anti-OVA IgG1 from mice at 14 days post immunization with
PBS, OVA/ISCOMATRIX with the injection site intact or OVA/ISCOMATRIX with the injection site removed shortly following immunization. Groups contained 3 animals
and data is representative of two independent experiments. IMX = ISCOMATRIXTM adjuvant.
(Supplementary Figure 2) (1). Mice were immunized with the
E-alpha peptide conjugated to OVA (OVA-Eα) with or without
ISCOMATRIX and mice immunized with PBS or ISCOMATRIX
alone were used as controls. The populations of monocytes, DCs
and SCSmacrophages were identified (Figure 6A) and the degree
of antigen presentation on these populations assessed by YAe
staining. At 4 h post-immunization, antigen presentation was
primarily detected on CD11b-CD11c+ and CD11b+CD11c+
DCs in both the presence and the absence of ISCOMATRIX
(Figures 6B,C). Antigen presentation was also observed on
CD169+ SCS macrophages at 4 h, however this was only
detectable in the absence of ISCOMATRIX (Figure 6D). Antigen
presentation waned rapidly in the absence of ISCOMATRIX, and
was no longer detectable 24 h after immunization (Figures 6B,C).
By contrast, ISCOMATRIX and OVA-Eα immunization resulted
in antigen presentation by CD11b+CD64+ monocytes that
actually increased at 24 h (Figure 6E). To identify which cell
population was functionally presenting antigen to T cells, we
performed in vivo multiphoton imaging of OTII DSRed T
cells in the popliteal lymph node of LysM-EGFP mice 24 h
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FIGURE 4 | ISCOMATRIX localizes to the subcapsular sinus macrophages and these cells are lost from the lymph node following ISCOMATRIX treatment. (A)
Mulitphoton image showing a popliteal lymph node labeled in vivo with a PE conjugated anti CD169 antibody and subsequently treated with 1 IU ISCOMATRIX-647 in
the footpad. Imaging was performed 1 h after treatment with the ISCOMATRIX-647. (B) CD169 Immunohistochemical staining of cervical lymph nodes 24 h following
immunization in the ear pinnae with either PBS or ISCOMATRIX. (C) Mulitphoton image showing the popliteal lymph node approximately 2 h following the
co-administration of the cell impermeable DNA dye Sytox orange and ISCOMATRIX-647 in the footpad. (D) Representative plots showing CD169 and CD64
expression on Ly6G- CD11b+ cells in the draining lymph node from mice treated with PBS or ISCOMATRIX at 24 h. (E) Flow cytometry data showing the percentage
and number of CD11b+ cells that are CD169+ SCS macrophages in the cervical lymph node at 24 h following immunization with PBS or ISCOMATRIX in the ear
pinnae. (F) The percentage of CD11b+ cells that are CD169+ SCS macrophages in the cervical lymph node over the first 12 h following immunization with PBS or
ISCOMATRIX in the ear pinnae. (G) The recovery of the of CD11b+ cells that are CD169 + SCS macrophages in the cervical lymph node over 28 days following
immunization with PBS or ISCOMATRIX in the ear pinnae. Groups contained 3 animals. IMX, ISCOMATRIXTM adjuvant, **P < 0.01, ***P < 0.001 ***P < 0.0001.
following immunization with OVA and ISCOMATRIX. While
GFP is strongly expressed in neutrophils in these mice, it is
also expressed in monocytes (Supplementary Figures 3A,B),
which are more numerous in the draining lymph node 24 h
post ISCOMATRIX immunization (Figure 2) in addition
monocytes express higher levels of MHCII relative to neutrophils
(Supplementary Figure 3C). These images show that following
immunization with OVA/ISCOMATRIX, antigen-specific T
cells interact with monocytes in the draining lymph node
(Supplementary Video 1). Previous studies by both our
laboratory and by others have demonstrated that the duration
of T cell interactions with APCs is functionally important in
driving T cell responses, with longer duration interactions
driving stronger responses (25–29). Here the comparison of
T cell monocyte interaction duration between ISCOMATRIX
immunized and unimmunized animals is not possible due to
the low numbers of monocytes present within lymph nodes.
However, analysis of T cell—monocyte interaction duration in
OVA/ISCOMATRIX immunized lymph nodes showed a similar
distribution of interaction lengths as is observed between T
cells and CD11c+ DCs following immunization with OVA and
LPS at ∼20 h (Figure 6F, Supplementary Video 1). While the
T cell—monocyte interaction duration following immunization
with ISCOMATRIX and bovine serum albumin (a non-cognate
antigen for OTII T cells) and the interaction duration between T
cells and CD11c+ DC in naïve mice are also similar (Figure 6F).
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Collectively, these data suggest the interactions between T
cells and monocytes that formed after immunization with
OVA/ISCOMATRIX were both antigen specific and functional.
A Novel Cellular Pathway of Antigen
Presentation Stimulates Robust Tfh and
Germinal Center B Cell Responses
We have shown that the recruited monocytes are able to form
interactions with CD4+ T cells and although it has previously
been shown that there is a requirement for CD4+ T cells in
the development of both ISCOMATRIX driven CD8+ T cell
and antibody responses in vivo (17) it is not known how the
CD4+T cell response develops following antigen presentation by
monocytes. We therefore utilized a transgenic TcR and BcR cell
adoptive transfer model to determine the effect of ISCOMATRIX
on this aspect of the immune response (30). Following adoptive
transfer of OVA-specific CD4+ OTII T cells and HEL-specific
MD4 B cells, recipient mice were immunized with HEL-OVA
in the presence or absence of ISCOMATRIX. Five days after
immunization, OVA-HEL co-administered with ISCOMATRIX
induced a significant expansion of OVA-specific OTII T cells
compared with antigen administered alone (Figure 7A). A
significant increase in numbers of antigen specific Tfh (PD1+
CXCR5+) was also observed at day 5 (Figures 7B,C); while by
day 7 an increased number of HEL specific germinal center B cells
was observed in mice receiving ISCOMATRIX compared with
antigen alone (Figures 7D,E,F). By day 14 this had translated into
ISCOMATRIX driven increases in serum titres of HEL specific
IgMa and of OVA specific IgG1 and IgG2c (Figure 7G).
DISCUSSION
The current studies demonstrate unequivocally that the adjuvant
co-administered with an antigen can obviate the requirement for
the skin to lymph node migration of tissue resident or recruited
DCs, or other innate cells to elicit an antigen specific CD4T
cell responses. We have in fact discovered an entirely novel
pathway whereby antigen bearing SCS macrophages are killed
by the associated adjuvant, internalized by monocytes recruited
from the circulation and it is these cells that appear to respond
to ISCOMATRIX adjuvant by increasing antigen presentation
to naïve CD4T cells resulting in a robust antibody response.
This finding has important implications for vaccine design and
delivery.
The activation of, and acquisition of antigen by DCs in
peripheral tissues followed by their migration to lymph nodes is
considered a key step in the induction of an adaptive immune
response (1, 3). The ability of adjuvants to initiate or enhance this
process is thought to underlie their immunostimulatory function
(18). Using the photoconvertable (Kaede) mouse model (21), we
demonstrated that injection of antigen and ISCOMATRIX fails to
induce skin to lymph node migration of any cells, including DCs.
Furthermore, tissue ablation demonstrated no role for cells and
mediators resident or induced at the injection site in mediating
the adjuvant activity of ISCOMATRIX. By contrast, we have
recently shown that the very rapid (<2 h) inflammatory response
induced at the injection site by Alum adjuvant does play a role in
adjuvant activity, through generation of neutrophil NETS which
subsequently affect T and B cell responses in the draining lymph
node (31). In the case of ISCOMATRIX, the lack of a requirement
for tissue inflammatory responses was consistent with the rapid
translocation of antigen and adjuvant to the draining lymph
node, which was almost complete 15min after injection. This
rapid displacement of ISCOMATRIX to the draining lymph node
can be explained by the physical nature of this adjuvant. While
particles >200 nm generally require clearance by migratory
phagocytes, nanoparticles in the range 10–200 nm can directly
enter lymphatic vessels by diffusion through flap valves between
lymphatic endothelial cells (32). ISCOMATRIX particles are
∼40–50 nm in diameter (33), suggesting their rapid exit from
the injection site may occur via this pathway. After entry into
lymphatic vessels, fluid and small particles subsequently enter the
lymph node in the SCS (13, 15). Soluble material, such as proteins
<70 kDa can directly access the T cell areas of the lymph node
through entry into the fibroblastic reticular cell (FRC) conduit
system (34). By contrast, larger particles, including bacteria and
viruses are retained in the SCS and are sampled by CD169+
macrophages (35, 36). Intravital imaging demonstrated that
ISCOMATRIX accumulates in SCS macrophages and resulted
in cell killing, producing almost complete depletion of this cell
population within 12 h of ISCOMATRIX administration. This in
vivo observation is consistent with previous in vitro data showing
ISCOMATRIX internalization directly results in inflammasome
activation, and subsequent death of peritoneal macrophages
(37). Recently, inflammatory stimuli such as TLR9 agonists and
vaccinia virus have been shown to mediate loss of the SCS
macrophage population in the lymph node (38). Furthermore,
it has been shown that vaccinia virus induces inflammasome
activation and death of SCS macrophages by pyroptosis. This
results in release of extracellular ASC specks which drive lymph
node inflammation (39), while other work using an attenuated
influenza vaccine has shown a role for TLR7 signaling in
the death of SCS macrophages and subsequent IL-1α release
(40). The previously shown partial reduction of ISCOMATRIX
adjuvant activity in ASC and caspase- 1/11 deficient mice, and
the ISCOMATRIX driven in vitro death of macrophages in
combination with our data suggests that SCS macrophages may
be a key point where innate immune activation plays a role in
mediating ISCOMATRIX adjuvant activity (37).
At this point our own studies and those described failed
to explain how pyroptosis of SCS macrophages could lead to
antigen presentation to naïve T cells. Surprisingly, labeling of
SCS macrophages conclusively demonstrated that cell debris was
not taken up by DCs, but by CD64+/Ly6C+ monocytes that
were recruited to the lymph node in response to ISCOMATRIX
treatment. We furthermore confirmed that these recruited
monocytes not only presented antigen but also formed cognate
interactions with antigen specific CD4+ T cells. While these
studies do not disprove a role for lymph node resident DC in
antigen presentation, the increase in antigen presentation by
monocytes, and not DC induced by adjuvant, suggests these
cells are responsible, at least in part for ISCOMATRIX adjuvant
activity.
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FIGURE 5 | SCS macrophages are taken up by monocytes following immunization with ISCOMATRIX. (A) Representative flow cytometry plots showing in vivo
antibody staining with eFluor660 conjugated anti-CD169 prior to treatment with PBS (top) and ISCOMATRIX (middle) or the isotype control antibody (bottom)
treatment in the ear pinnae. (B) Representative histograms and MFI (points = individual animals, lines show mean±SEM) of ex vivo PE conjugated anti-CD169 (top);
anti-CD64 (middle), and anti-Ly6C (bottom) on cells positive for the in vivo CD169 label. Groups contained 3 animals and data is representative of two independent
experiments **P < 0.01. (C) Representative imaging flow cytometry images showing monocytes at 24 h post-immunization with ISCOMATRIX from the lymph nodes
of mice following in vivo eFluor660 conjugated anti-CD169 (top) or the isotype control (bottom) labeling. (D) Representative imaging flow cytometry images showing
macrophages (CD11b+) at 24 h post-immunization with PBS from the lymph nodes of mice following in vivo eFluor660 conjugated anti-CD169 labeling. The
anti-CD169 antibody treated group contained 3 animals, while the isotype control treated group contained 2 animals. IMX = ISCOMATRIXTM adjuvant.
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FIGURE 6 | Recruited monocytes present antigen and may be observed interacting with T cells in the lymph node at 24 h post-immunization. (A) Representative plots
showing flow cytometry gating strategy for the identification of CD11b+CD64+ monocytes, for CD11b+CD169+ SCS macrophages and CD11b- or CD11b+
CD11c+MHCII+ dendritic cells. Graphs showing mean (±SEM) YAe MFI on CD11b- (B) and CD11b+ (C) dendritic cells at 4, 24, and 48 h; mean (±SEM) YAe MFI
SCS macrophages (D) at 4 h; mean (±SEM) YAe MFI on monocytes (E) at 4, 24, and 48 h. Groups contained 3 animals and data is representative of three
independent experiments. (F) LysM-EGFP or CD11cYFP mice were immunized in the footpad (OVA or BSA/ISCOMATRIX or OVA/LPS respectively) ∼20 h later the
draining popliteal lymph node was surgically exposed. OTII DSRed T cells and monocytes (GFP+) or DCs (YFP+) were imaged by live real time multiphoton
microscopy. Interaction between T cells and monocytes (and T cells and DCs was identified by colocalization of the DSRed signal with the GFP or YFP signals and
tracked for up to 20min, 48 such interactions were tracked in the OVA/ISCOMATRIX treated mice. IMX = ISCOMATRIXTM adjuvant, *P < 0.05, **P < 0.01,
***P < 0.001 ****P < 0.0001.
The canonical model of T cell activation via the migration of
activated DCs from the site of injection to the draining lymph
node has relevance to some immunostimulatory adjuvants.
However, given the broad range of agents with adjuvant activity,
such a model was unlikely to explain how all adjuvants work.
Furthermore, a clear outcome from this model was that adjuvant
activity required initiation of injection site inflammation to
drive recruitment and/or migration of DCs from the tissue.
This is clearly a challenge to the production of vaccines that
minimize injection site reactions and associated pain. Therefore,
an ideal adjuvant would target immune interactions in the
draining lymph node, generating good antigen specific T and B
cell responses, while avoiding injection site reactions. While we
identified that ISCOMATRIX does induce local inflammation,
this was dispensable for adjuvant action. In dissecting the
underlying mechanism that allows ISCOMATRIX to drive
adjuvant activity in the lymph node, we have identified an entirely
novel pathway that contrasts with the existing dogma explaining
the initiation and enhancement of the immune response.
MATERIALS AND METHODS
Mice
Seven to Ten week-old male C57BL/6J mice were purchased
from Charles River Laboratories (Bicester UK). OT-II TCR Tg
mice (41) and MD4 BcR Tg mice (42) on C57BL/6 backgrounds
were used as a source of OVA specific T cells and HEL specific
B cells respectively. Kaede mice were obtained from Michio
Tomura (Yokohama); these mice have the Kaede fluorescent
protein green knocked in under the control of a synthetic beta-
actin promoter. As a result all cells express the photoconvertable
kaede protein (21). LysM-EGFP mice were a kind gift from
Professor Sussan Noursargh. These mice have the gene for EGFP
knocked into the Lysozyme (Lys) M locus resulting in mice
with fluorescent myelomonocytic cells, with neutrophils being
EGFPhi and monocytes EGFPlow. CD11cYFP mice express YFP
under the control of the CD11c promoter resulting in YFP
expression in all CD11c+ cells (43). hCD2-DsRedmice (gifted by
D Kioussis and A Patel, National Institute for Medical Research,
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FIGURE 7 | ISCOMATRIX stimulates Tfh and germinal center B cell responses. (A) Total number of OVA specific (OTII) CD4+ T cells in the lymph node, and (B) the
number are CXCR5+PD1+ at 5 and 7 days. (C) Representative flow cytometry plots showing CXCR5 and PD1 staining on OTII CD4+ T cells from OVA-HEL and
OVA-HEL/ISCOMATRIX treated mice at 5 days. (D) Total number of HEL specific (MD4) B cells and (E) the number that are GL-7+/FAS+ at 7 days. (F)
Representative flow cytometry plots showing GL-7 and FAS staining on MD4 B cells from OVA-HEL and OVA-HEL/ISCOMATRIX treated mice at 7 days. (G) Graphs
showing the mean ± SEM serum anti-HEL IgMa, anti-OVA IgG1, and anti-OVA IgG2c titers at 14 days post-immunization with OVA-HEL, OVA-HEL/ISCOMATRIX or
PBS. Immunized groups contained 3 animals and are representative of 2 independent experiments. IMX = ISCOMATRIXTM adjuvant, *P < 0.05, ***P < 0.001,
****P < 0.0001.
London) were crossed with OVA specific OT-II (41) TCR
Tg mice.
Animals were maintained under standard animal house
conditions at the University of Glasgow and procedures were
performed under a UK Home Office license in accordance with
UK Home Office regulations following review by the University
of Glasgow Ethics Committee.
Immunization, Adjuvant, and Antigens
All mice were either injected subcutaneously (s/c) in the ear
pinna with 10 µL or in the footpad 25 µL of antigen/adjuvant
solutions. Mice were immunized with either 100 µg of
chromatographically purified chicken ovalbumin (OVA;
Worthington Biochemical, Lakewood, NJ, USA); 100 µg of
bovine serum albumin (BSA; Sigma Aldrich, Dorset, UK); with
50 µg OVA-conjugated to the Eα peptide (ALMAC, Scotland,
UK); for the whole-body imaging experiments mice were
immunized with 30 µg OVA conjugated to AlexaFluor 790,
this was prepared according to the manufacturer’s instructions
using the AlexaFluor790 NHS ester (ThermoFisher). In other
experiments mice were immunized with 50 µg OVA-HEL
conjugate prepared using glutaraldehyde to couple the chicken
OVA and HEL (Sigma Aldrich, Dorset, UK) as previously
published (30). Antigens were given with 1 IU ISCOMATRIX
(CSL Limited, Australia), in some experiments or some control
animals received ISCOMATRIX alone. In other experiments
ISCOMATRIX labeled with the fluorescent dyes AlexaFluor
647 (CSL Limited, Australia) was used. For the identification of
dying cells Sytox Orange (ThermoFisher) was administered with
ISCOMATRIX. Control mice for the cell migration experiment
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were injected with 1% Alum suspension (a kind gift from Dr Erik
Lindblad, Brenntag Biosector, Denmark) and 8 µg LPS (E. coli
0111:B4; Sigma Aldrich, UK).
Flow Cytometry
Ear tissue was cut up into∼2mm× 2mm pieces and digested in
2 mg/mL Collagenase IV; 2 mg/mL Hyaluronidase (both Sigma
Aldrich) and 100 U/mL DNaseI (ThermoFisher Scientific) at
37◦C for 30min. Following digestion tissue was homogenized
using a gentleMACs Dissociator (Miltenyi Biotech, UK). The
draining superficial cervical or popliteal lymph nodes were
gently mashed against nitex (Cadisch Precision Meshes, UK)
using the rubber end of a syringe plunger and digested in 2.68
mg/mL collagenase D (Roche) for 25min at 37◦C. The enzymatic
reaction was stopped by adding EDTA to a final concentration of
10mM. A single cell suspension was then obtained by passing the
lymph node or tissue suspensions through a 70µm cell strainer.
Single cell suspensions were then stained with combinations
of the following antibodies: anti-CD11c (N418;), anti-CD11b
(M1/70), anti-CD45 (30-F11), anti-MHCII (M5/114.15.2), anti-
CD169 (SER4); anti-B220 (RA3-6B2) (all eBioscience, Hartfield,
UK); or anti-GL-7 (GL7), anti-FAS-PE-Cy7 (Jo2) anti-CD45.1
(A20), anti-Vb5.1/5.2 (MR9-4) (all BD Biosciences,) or anti-
CD4 (GK1.5), anti-CD64 (X54-5/7.1), and anti-Ly6-G (IA8)
(all BioLegend, London, UK), conjugated to the following
fluorochromes as appropriate Alexafluor488, AlexaFluor647,
APC, APC-Cy7, APC-eFluor780; Brilliant Violet 421, eFluor450,
eFluor660, eVolve605, FITC, PE, PE-Cy5, PE-Cy7, PERCPCy5.5
or PERCP-eFluor710. Biotinylated antibodies against YAe (YAe-
eBio; eBiosciences) and IgMa (DS-1; BD Biosciences) were also
used where appropriate and detected with either Streptavidin
APC or APC-eFluor780 (eBiosciences) as appropriate. Antibody
staining was performed in conditioned media from the anti-
CD16/CD32 antibody producing hybridoma (2.4G2) (FcBlock).
The viability of the cells was confirmed using fixable eFluor450,
eFluor506, or eFluor780 viability dyes (eBioscience). Samples
were acquired using a LSRII flow cytometer running FACDiva
software (both BDBiosciences) and or on a MACSQuant flow
cytometer (Miltenyi Biotech, UK). Analysis was performed using
FlowJo software (Version 10.0.8; Treestar).
Enzyme Linked Immunosorbant Assay
(ELISA)
HEL specific IgMa or OVA specific IgG1 and IgG2a/IgG2c titres
were determined in serum samples collected 14 and 21 days after
immunization as previously described (44).
Whole Body in vivo Optical Imaging
Images were acquired on a Kodak in vivo imaging system FX
Pro (Carestream, Hertfordshire, UK). Animals were anesthetized
using an isoflurane/oxygen mixture and fur removed from the
ear and neck with depilatory cream (Boots the Chemist, UK).
The mouse was placed on its side in the imaging so that
both the ear and the draining Lymph node were facing the
camera and light source. Imaging was performed at intervals
following administration of fluorescently labeled ISCOMATRIX-
647 and/or antigen (OVA-790). Band-pass excitation filters of
630 ± 10 nm was used for the visualization of ISCOMATRIX-
647 and 770 ± 10 nm for OVA-790; emission filters were 700 ±
17.5 nm and 830 ± 17.5 nm respectively. The exposure time for
fluorescent images was 120 s, with 1 × 1 pixel binning and an
aperture f-stop of 2.51. X-Ray images were taken using a 0.4mm
aluminum filter with an exposure time of 60 s, 1× 1 pixel binning
and an aperture f-stop of 3.99. The entire acquisition time
per animal was ∼10min. Image processing and analysis were
performed using the Carestream molecular Imaging software
(CarestreamHealth, Inc., Rochester, NY). Fluorescent images are
displayed as pseudo-colored overlaid on the x-ray images. Scaling
was determined manually and applied by the imaging software to
the acquired gray-scale fluorescent images. Quantification of the
fluorescence signal in the ear and the draining lymph node was
determined using a region of interest (ROI) tool to carefully draw
around the ear and around the location of the lymph node. The
total fluorescence intensity (FI) in arbitrary units for each ROI
was then determined by the software.
Photoconversion of Kaede Mouse Footpad
Photo-conversion of the Kaede mouse tissue was performed
using a small mains operated 12x S06J bluray diode with a 405-G-
2-glass lens (DTR’s Laser Shop). The 405 nm laser diode operates
at 600–650mW, the emission spectra lies at 405 nm. Immediately
prior too or at various times post-immunization (as detailed in
the figure legend) mice were anesthetized and the ventral and
dorsal sides of the tissue (hind paw) was illuminated on both sides
with the laser for three times 5 s bursts. A 3 s interval between
each burst was included to avoid tissue damage. The tissue was
only photo-converted once per animal.
In vivo Labeling of SCS Macrophages
eFluor660 or PE conjugated anti-CD169 (clone SER4) or Isotype
control (clone) were purchased from eBiosciences, azide was
removed by diafiltration and the antibody concentrated to ∼1
mg/mL. 24 h prior to immunization 0.5 µg of antibody in
10 µL was injected into the ear pinnae (for flow cytometery
experiments) or in 25 µL into the footpad (for imaging
experiments).
ImageStream Analysis
Single cell suspensions were prepared from lymph nodes as
described above for flow cytometry. Cells where stained with
anti-CD11b (M1/70) conjugated to AlexaFluor 488 and anti-
CD64 (X54-5/7.1) conjugated to Brilliant Violet 421 diluted in
FcBlock. Samples where acquired on an Amnis ImageStream X
MKII (EMDMillipore) equipped with 405, 488, 561, and 642 nm
lasers and 6 detector channels using the 40 x objective. Data was
analyzed using the IDEASTM software (EMDMillipore).
In vivo Multiphoton Imaging
Multiphoton imaging was performed with a Zeiss LSM7
MP system equipped with both a 10x/0.3 NA air and a
20x/1.0NA water immersion objective lens (Zeiss) and a
tuneable titanium/sapphire solid state 2-photon excitation source
(Chamelon Ultra II; Coherent Laser Group). For in vivo imaging,
animals were anesthetized with 3% isoflurane in 1.5 L/min
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oxygen, anesthesia was maintained with the isoflurane at 1.5–
2%, and oxygen at 1.5 L/min. Core body temperature was
continuously monitored and maintained by a thermostatically
controlled heat mat. The popliteal was surgically exposed and the
leg fixed in place using surgical veterinary glue (Vetbond; 3M).
The hind quarters of the mouse was submerged in PBS warmed
and maintained at 35–37◦C throughout the experiment (45).
Videos were acquired for 15–30min at an X-Y pixel resolution
512 × 512 with 2µm increments in Z. Images were processed
using Volocity 5.5 (Perkin Elmer) after correction for tissue drift.
Immunohistochemistry
Ear draining cervical lymph nodes were harvested and placed
in OCT cryomedia (Tissue-Tek) and frozen, 8µm sections
were cut and placed on glass slides, sections were briefly fixed
in acetone, rehydrated in PBS, nonspecific antibody binding
was blocked using 2.4G2 culture supernatant containing 0.01%
sodium azide, 5% mouse serum), followed 5% Normal Horse
Serum in PBS (Vector Laboratories) sections were stained with
anti-mouse-CD169 PE (BioLegend, clone:-3D6.112) antibodies
at 1:100 overnight at 2–8◦C in a humidity chamber. Sections
were washed and coverslips applied using ProLong Gold
Antifade (LifeTechnologies) to preserve fluorescence. Images
were acquired using EVOS R© FL Auto fluorescent microscope
and imaging system (LifeTechnologies) at 10X magnification
using the RFP detector. Final image processing was performed
using ImageJ software.
Statistics
Intergroup significance was determined by either a 1-way
ANOVA or a 2-way ANOVA using GraphPad Prism 6 (GraphPad
Software Inc, La Jolla, USA). A value of P ≤ 0.05 was considered
significant.
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Supplementary Figure 1 | SCS macrophage debris do not appear to be taken
up by CD11c+ DC. MFI of CD169 ex vivo on CD11b-CD11c+ DC at 4 (A) and 24
(B) h following immunization with PBS or 1 IU ISCOMATRIX and on
CD11b+CD64+ monocytes at 24 h (C) following immunization with 1 IU
ISCOMATRIX. ∗∗∗∗P < 0.0001. IMX, ISCOMATRIXTM adjuvant.
Supplementary Figure 2 | Detecting antigen presentation using the Yae-Eα
system. OVA-Eα is taken and processed up by the antigen presenting cell. The
resulting peptide antigens including Eα are loaded into MHCII and presented on
the cell surface to CD4+ T cells. The YAe antibody binds to the peptide-MHCII
complex essentially “seeing what the TCR sees,” and may be detected by flow
cytometry providing a direct measure of antigen presentation.
Supplementary Figure 3 | In the draining lymph nodes of LysM-EGFP mice
treated with ISCOMATRIX GFP+ monocytes express MHCII while GFP+
neutrophils do not. LysM GFP mice were treated with 1 IU ISCOMATRIX in the
footpad and the draining popliteal lymph node was harvested and analyzed by
flow cytometry for the expression of MHCII on neutrophils and monocytes. (A) A
representative FACS plot of Ly6G and CD64 expression on GFP+ cells.
Neutrophils are considered Ly6G hi while Monocytes are CD64+(B) A
representative histogram overlay shows the relative expression of GFP in
neutrophils and monocytes following ISCOMATRIX treatment. (C) Median
fluorescence intensity of MHCII on monocytes and neutrophils in the draining
lymph node following ISCOMATRIX treatment. IMX, ISCOMATRIXTM adjuvant.
Supplementary Video 1 | Following immunization with OVA/ISCOMATRIX T cells
can be observed interacting with monocytes. OTII DSRed T cells (red) can be
observed interacting (white) with GFP+ monocytes (green) in the popliteal lymph
node at 20 h post-immunization with OVA/ISCOMATRIX. Scale bar = 100 µm.
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